FBLIM1 (filamin binding LIM protein 1) serves as a cytoskeletal regulatory protein that anchors cell-ECM adhesion proteins and filamin-containing actin filaments, playing crucial roles in cell shape modulation and motility. The protein promotes dissociation of filamin A from integrins and regulates integrin activation and cell-cell adhesion. Recent studies have identified FBLIM1 as a critical checkpoint gene that maintains vascular smooth muscle cell contractile phenotype, with its dysregulation leading to cytoskeletal disarrangement and pathological arterial remodeling 1. In disease contexts, FBLIM1 demonstrates significant clinical relevance across multiple conditions. The protein is highly expressed in cancer-associated fibroblasts in non-small cell lung cancer, where FBLIM1-positive CAFs correlate with increased TGF-β expression, epithelial-mesenchymal transition, and immunosuppressive tumor microenvironments, serving as a poor prognostic marker for immunotherapy 2. FBLIM1 also drives liver fibrosis through TGF-β signaling regulation via WTAP-mediated m6A modification 3. Additionally, rare variants in FBLIM1 are associated with chr1 non-bacterial osteomyelitis, with approximately 22% of Italian CNO patients carrying rare coding variants 4. In oral cancer, FBLIM1 upregulation enhances malignancy through EGFR pathway modulation 5.